Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03582267
Other study ID # 1706-066-1706
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2017
Est. completion date August 1, 2019

Study information

Verified date September 2019
Source Texas Christian University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nutrition interventions may present a safe and relatively risk free intervention for protection against subconcussive impacts. Docosahexaenoic acid (DHA, 22:6n-3) is the principal Omega 3 polyunsaturated fatty acid in the brain, playing an integral role in the brain's development and structural integrity. The goal of this study is to determine if supplementation with DHA attenuates blood biomarkers of repetitive head trauma linked to sub-concussive impacts sustained in rugby participation.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date August 1, 2019
Est. primary completion date August 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Canadian national rugby athletes on 7s and 15s teams

Exclusion Criteria:

- None

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Docosahexaenoic Acid (DHA)
Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.

Locations

Country Name City State
United States Texas Christian Universti Fort Worth Texas

Sponsors (1)

Lead Sponsor Collaborator
Texas Christian University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood concentration of neurofilament light protein Concentrations of neuronally derived proteins measured in blood 12 times throughout course of 1 year
See also
  Status Clinical Trial Phase
Completed NCT03291964 - Rapid MRI for Acute Pediatric Head Trauma
Completed NCT02828306 - Computer Based Algorithm for Patient Specific Implants for Cranioplasty in Patients With Skull Defects
Completed NCT04505293 - Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas N/A
Not yet recruiting NCT02232347 - Ketamine and Glutamate After Brain Injury : a Microdialysis Study Phase 2
Completed NCT01448473 - Is a Two-Film Skull X-ray Series as Sensitive as a Four-Film Series in the Diagnosis of Skull Fractures in Paediatric Patients N/A
Terminated NCT00847977 - Interest of Using Balanced Fluid for Infusion at the Early Phase of an Acute Cranial Trauma for Limiting Hyperchloremic Acidosis Phase 3
Completed NCT00622778 - Immunemodulation in Patients With Minor Head Injury N/A
Completed NCT04495634 - Evaluation of a Carbon Nanotube Enabled Solid-State Head CT N/A
Terminated NCT03680911 - NAC for Head Trauma-induced Anosmia Phase 3
Recruiting NCT06173427 - Monitoring of Intracranial Hemorrhage in Non-severe Head Trauma Patients Hospitalized in the UHCD
Completed NCT03742427 - Effect of Cervical Collar on the Optic Nerve Sheath Diameter in Minor Head Trauma N/A
Terminated NCT06246500 - Severe Head Trauma: Coagulation and CT-Scan Aggravation.
Withdrawn NCT03453749 - Anti-secretory Factor as a Treatment for Adults With Severe Traumatic Head Injury Phase 2
Completed NCT00995683 - Preventive Sodium Lactate and Traumatic Brain Injury Phase 2/Phase 3
Not yet recruiting NCT05195606 - The Effect of Auditory and Tactile Stimuli in Traumatic Coma N/A
Completed NCT04020874 - Reducing Head Impact Exposure in Hawaii High School Football N/A
Not yet recruiting NCT06113939 - Prevention of Infection of the Respiratory Tract Through Application of Non-Invasive Methods of Secretion Suctioning N/A
Recruiting NCT05386966 - Medicolegal Aspects of Head Trauma
Not yet recruiting NCT03704272 - Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral N/A
Active, not recruiting NCT00196131 - Problems With Morphine Use in Patients With a Severe Brain Injury Phase 1/Phase 2